As shown in Fig. 3k and Supplementary Fig. S4g, treatment with Ruxolitinib or IFNAR neutralizing antibody resulted in a reduction of proinflammatory chemokines and cytokines induced by trVLP-3Mut infection, restoring them to the levels observed in trVLP-WT. This evidence concerns the gene IFNAR1 and infection.